- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03200977
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
March 14, 2022 updated by: Bristol-Myers Squibb
Observational Cohort Study to Characterize the Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will include a retrospective and prospective observational database analysis.
Study Type
Observational
Enrollment (Actual)
95
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Princeton, New Jersey, United States, 08540
- Bristol-Myers Squibb
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Center for International Blood and Marrow Transplant Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study will target enrollment of 90 patients who were treated with nivolumab-based regimen prior to an allogeneic HCT with at least 45 patients who received nivolumab immediately prior to the allogeneic HCT
Description
Inclusion Criteria:
- Age greater than or equal to18 years;
- First allogeneic HCT for cHL;
- Patients with prior autologous HCT for cHL;
- Any conditioning regimen, graft source or donor type.
- For the primary analysis additional criterion includes prior exposure to nivolumab for treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used alone or in combination with other agents and used as the last line of therapy prior to an allogeneic HCT with the interval between the last dose of nivolumab and start of the conditioning regimen no longer than 12 months.
Exclusion Criteria:
- Patients with nodular lymphocyte-predominant HL
- Previous chimeric antigen receptor T-cell therapy or other genetically modified cellular product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Exposed to nivolumab prior to allogeneic HCT
patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
|
Non-Interventional
|
Unexposed to nivolumab prior to allogeneic HCT
patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
|
Non-Interventional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Related Mortality (TRM)
Time Frame: At 6 months after an allogeneic HCT
|
Treatment-Related Mortality at 6 months after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
|
At 6 months after an allogeneic HCT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of disease progression
Time Frame: Up to 2 years
|
Measured by clinical assessment
|
Up to 2 years
|
Incidence of acute Graft Versus Host Disease (GVHD)
Time Frame: Up to 2 years
|
Either Grade II-IV or Grade III-IV acute GVHD.
Measured by clinical assessment
|
Up to 2 years
|
Incidence of chronic Graft Versus Host Disease (GVHD)
Time Frame: Up to 2 years
|
Measured by clinical assessment
|
Up to 2 years
|
Incidence of post-transplant sinusoidal obstruction syndrome (SOS)
Time Frame: Up to 2 years
|
Measured by clinical assessment
|
Up to 2 years
|
Incidence of post-transplant interstitial pneumonitis (IPN)
Time Frame: Up to 2 years
|
Measured by clinical assessment
|
Up to 2 years
|
Incidence of post-transplant renal toxicity requiring dialysis
Time Frame: Up to 2 years
|
Measured by clinical assessment
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
OS is measured from the date of allogeneic transplant to death.
|
Up to 2 years
|
Progression-Free Survival (PFS)
Time Frame: Up to 2 years
|
PFS is measured from the date of allogeneic transplant to the date of disease progression or death.
|
Up to 2 years
|
TRM at 100 days
Time Frame: At 100 days after an allogeneic HCT
|
Treatment-Related Mortality at 100 days after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
|
At 100 days after an allogeneic HCT
|
TRM at 1 year
Time Frame: At 1 year after an allogeneic HCT
|
Treatment-Related Mortality at 1 year after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
|
At 1 year after an allogeneic HCT
|
TRM at 2 years
Time Frame: At 2 years after an allogeneic HCT
|
Treatment-Related Mortality at 2 years after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
|
At 2 years after an allogeneic HCT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2016
Primary Completion (Anticipated)
June 1, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
June 26, 2017
First Submitted That Met QC Criteria
June 26, 2017
First Posted (Actual)
June 27, 2017
Study Record Updates
Last Update Posted (Actual)
March 29, 2022
Last Update Submitted That Met QC Criteria
March 14, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA209-835
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
BioNova Pharmaceuticals (Shanghai) LTD.TerminatedFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaChina
-
Tessa TherapeuticsActive, not recruitingAnaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)United States
-
Royal Marsden NHS Foundation TrustUnknownMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)United Kingdom
-
AmgenCompletedLymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
Reid Merryman, MDGenentech, Inc.RecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin LymphomaUnited States
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaAustralia
Clinical Trials on Non-Interventional
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Not yet recruiting
-
Papworth Hospital NHS Foundation TrustLifeArcNot yet recruitingNon-cystic Fibrosis BronchiectasisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruitingGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Oesophageal Cancer | Hepato-Biliary Carcinoma in Situ NosUnited Kingdom
-
Shanghai Zhongshan HospitalRecruiting
-
Ankara UniversityRecruiting
-
Chinese University of Hong KongJockey Club Centre for Positive AgeingNot yet recruiting